Verification of the interaction between peptide T and CD4 using surface plasmon resonance.

Abstract

Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. Its putative mode of action is inhibition of binding of the HIV envelope protein (gp120) to its cellular receptor (CD4), thus preventing viral infectivity and gp120-induced neuronal toxicity. However, a number of reports have appeared in the literature which have failed to observe any inhibitory activity of Peptide T on CD4-gp120 binding, thus casting doubt on this hypothesis. This study uses a novel biosensor technique to demonstrate that Peptide T does bind to CD4 and that this binding can be specifically inhibited by an anti-CD4 monoclonal antibody. A detailed analysis of the kinetics of the interaction is presented.

• Authors: T E Ramsdale, P R Andrews, E C Nice
• Journal: FEBS letters (FEBS Lett) Vol. 333 Issue 3 Pg. 217-22 (Nov 01 1993) ISSN: 0014-5793 [Print] England
• PMID: 8224182 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• CD4 Antigens
• Peptide T

Topics

• Amino Acid Sequence
• Antibodies, Monoclonal (metabolism)
• CD4 Antigens (chemistry, metabolism)
• Kinetics
• Mathematics
• Molecular Sequence Data
• Peptide T (chemistry, metabolism)
• Protein Binding